Mechanistically, BCL6 suppress pro-inflammatory cytokines expression by HCC cancer cells and promoted the expression of immune suppressive protein ESM1, which was reported to be antagonist of ICAM-1 in binding to T cell surface protein LFA-1. Here, ICAM1 is linked to cancer.